JP7098520B2 - 細胞傷害性免疫刺激性粒子及びその使用 - Google Patents

細胞傷害性免疫刺激性粒子及びその使用 Download PDF

Info

Publication number
JP7098520B2
JP7098520B2 JP2018520152A JP2018520152A JP7098520B2 JP 7098520 B2 JP7098520 B2 JP 7098520B2 JP 2018520152 A JP2018520152 A JP 2018520152A JP 2018520152 A JP2018520152 A JP 2018520152A JP 7098520 B2 JP7098520 B2 JP 7098520B2
Authority
JP
Japan
Prior art keywords
rna
protamine
cytotoxic
nucleotide
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018520152A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018535206A (ja
JP2018535206A5 (enExample
Inventor
パスコロ，スティーブ
Original Assignee
バイオンテック エスエー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオンテック エスエー filed Critical バイオンテック エスエー
Publication of JP2018535206A publication Critical patent/JP2018535206A/ja
Publication of JP2018535206A5 publication Critical patent/JP2018535206A5/ja
Priority to JP2022104427A priority Critical patent/JP7250986B2/ja
Application granted granted Critical
Publication of JP7098520B2 publication Critical patent/JP7098520B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2018520152A 2015-10-21 2016-10-20 細胞傷害性免疫刺激性粒子及びその使用 Active JP7098520B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022104427A JP7250986B2 (ja) 2015-10-21 2022-06-29 細胞傷害性免疫刺激性粒子及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2015/074386 2015-10-21
PCT/EP2015/074386 WO2017067592A1 (en) 2015-10-21 2015-10-21 Cytotoxic immunostimulating particles and uses thereof
PCT/EP2016/075146 WO2017068013A1 (en) 2015-10-21 2016-10-20 Cytotoxic immunostimulating particles and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022104427A Division JP7250986B2 (ja) 2015-10-21 2022-06-29 細胞傷害性免疫刺激性粒子及びその使用

Publications (3)

Publication Number Publication Date
JP2018535206A JP2018535206A (ja) 2018-11-29
JP2018535206A5 JP2018535206A5 (enExample) 2019-08-29
JP7098520B2 true JP7098520B2 (ja) 2022-07-11

Family

ID=54478716

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018520152A Active JP7098520B2 (ja) 2015-10-21 2016-10-20 細胞傷害性免疫刺激性粒子及びその使用
JP2022104427A Active JP7250986B2 (ja) 2015-10-21 2022-06-29 細胞傷害性免疫刺激性粒子及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022104427A Active JP7250986B2 (ja) 2015-10-21 2022-06-29 細胞傷害性免疫刺激性粒子及びその使用

Country Status (6)

Country Link
US (2) US10980875B2 (enExample)
EP (1) EP3365010B1 (enExample)
JP (2) JP7098520B2 (enExample)
AU (1) AU2016341178B2 (enExample)
CA (1) CA3002288C (enExample)
WO (2) WO2017067592A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017067592A1 (en) 2015-10-21 2017-04-27 Biontech Ag Cytotoxic immunostimulating particles and uses thereof
WO2018134254A1 (en) 2017-01-17 2018-07-26 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
SG11202101732WA (en) 2018-10-01 2021-03-30 Univ Mainz Johannes Gutenberg Rna particles comprising polysarcosine
WO2021001023A1 (en) * 2019-07-02 2021-01-07 Biontech Rna Pharmaceuticals Gmbh Rna formulations suitable for therapy
CN113577039A (zh) * 2021-07-01 2021-11-02 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） 鱼精蛋白压缩dna后被红细胞膜包裹构成的纳米颗粒的应用及其制备方法
WO2025196322A2 (en) 2024-03-22 2025-09-25 BioNTech SE Cytotoxic polynucleotides, particles containing the cytotoxic polynucleotides and uses thereof
CN118845677B (zh) * 2024-07-09 2025-10-10 常州大学 一种阿霉素无定形固体分散体及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009144230A1 (en) 2008-05-26 2009-12-03 Universität Zürich Protamine/rna nanoparticles for immunostimulation
US20100310583A1 (en) 2007-01-31 2010-12-09 Immune Disease Institute Let-7 microrna and mimetics thereof as therapeutics for cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736531A (en) * 1987-10-28 1998-04-07 Pro-Neuron, Inc. Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
KR100334858B1 (ko) 1993-02-19 2006-01-27 니뽄 신야쿠 가부시키가이샤 핵산공중합체를함유하는의약조성물
US5457187A (en) * 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
CA2638906A1 (en) 2006-01-26 2007-08-16 University Of Massachusetts Rna interference agents for therapeutic use
JP4936312B2 (ja) 2006-07-20 2012-05-23 株式会社島津製作所 新規な両親媒性物質、それを用いた薬剤搬送システム及び分子イメージングシステム
EP2200639B1 (en) 2007-09-24 2016-03-30 Government of the USA, as Represented by the Secretary, Department of Health and Human Services Immunostimulatory combinations of tlr3 ligands with tlr2 and tlr9 agonists and methods of use
WO2009046739A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating prostate cancer (pca)
WO2010037408A1 (en) * 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
US20110300205A1 (en) 2009-07-06 2011-12-08 Novartis Ag Self replicating rna molecules and uses thereof
WO2011069529A1 (en) * 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
BR112014004544A2 (pt) 2011-08-31 2017-04-04 Mallinckrodt Llc modificação com peg de nanopartículas com h-fosfonatos
EP2942348B1 (en) 2014-05-07 2017-10-25 Johannes Gutenberg-Universität Mainz Thiol-protected amino acid derivatives and uses thereof
WO2016072500A1 (ja) 2014-11-08 2016-05-12 国立大学法人岡山大学 修飾ｒｎａを含有する分子集合体及びそれを用いたｒｎａ送達システム
WO2017067593A1 (en) 2015-10-21 2017-04-27 Biontech Ag Methods and means for inducing an immune response
WO2017067592A1 (en) 2015-10-21 2017-04-27 Biontech Ag Cytotoxic immunostimulating particles and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100310583A1 (en) 2007-01-31 2010-12-09 Immune Disease Institute Let-7 microrna and mimetics thereof as therapeutics for cancer
WO2009144230A1 (en) 2008-05-26 2009-12-03 Universität Zürich Protamine/rna nanoparticles for immunostimulation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Ｂｉｏｍａｔｅｒｉａｌｓ，2013年，Ｖｏｌ．３４，Ｐ．８４５９－８４６８，特にＡｂｓｔｒａｃｔ
Ｊｏｕｒｎａｌ ｏｆ ｃｏｎｔｒｏｌｌｅｄ ｒｅｌｅａｓｅ，2005年，Ｖｏｌ．１０６，Ｐ．１８１－１８７，特にＡｂｓｔｒａｃｔ
Ｍｏｌｅｃｕｌａｒ Ｔｈｅｒａｐｙ，2011年，Ｖｏｌ．１９、Ｎｏ．１１，Ｐ．２０４０－２０４７，特にＡｂｓｔｒａｃｔ、第２０４５頁のｓｉＲＮＡｓ

Also Published As

Publication number Publication date
US20180289797A1 (en) 2018-10-11
US20210205447A1 (en) 2021-07-08
WO2017068013A1 (en) 2017-04-27
AU2016341178B2 (en) 2023-02-23
CA3002288A1 (en) 2017-04-27
US12263215B2 (en) 2025-04-01
WO2017068013A9 (en) 2018-03-22
EP3365010C0 (en) 2024-01-03
JP2018535206A (ja) 2018-11-29
WO2017067592A1 (en) 2017-04-27
EP3365010B1 (en) 2024-01-03
US10980875B2 (en) 2021-04-20
CA3002288C (en) 2023-06-27
JP7250986B2 (ja) 2023-04-03
AU2016341178A1 (en) 2018-04-12
EP3365010A1 (en) 2018-08-29
JP2022130599A (ja) 2022-09-06

Similar Documents

Publication Publication Date Title
JP7250986B2 (ja) 細胞傷害性免疫刺激性粒子及びその使用
EP3758729B1 (en) Il-15 conjugates and uses thereof
US9636414B2 (en) Particles comprising single stranded RNA and double stranded RNA for immunomodulation
US20220273767A1 (en) Interleukin 10 Conjugates and Uses Thereof
US20220347308A1 (en) Methods and means for inducing an immune response
US10626400B2 (en) Stabilised formulations of RNA
CA3138430A1 (en) Microparticles and nanoparticles having sulfate groups on the surface
JP7520321B2 (ja) ＡタイプＣｐＧオリゴデオキシヌクレオチド含有脂質粒子
US10172960B2 (en) Particles comprising single stranded RNA and double stranded RNA for immunomodulation
KR20220092529A (ko) Nk 세포 수용체 결합을 위한 다중 리간드와 접합된 나노입자를 사용하는 암 치료 방법 및 조성물
WO2025196322A2 (en) Cytotoxic polynucleotides, particles containing the cytotoxic polynucleotides and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190719

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190719

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200623

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220520

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220531

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220629

R150 Certificate of patent or registration of utility model

Ref document number: 7098520

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250